ArticleBMC microbiology2025
Hyperproduction of nattokinase from Bacillus subtilis VIT MS2 using random mutagenesis and statistical optimization through central composite design.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Engineered Bacillus subtilis for high-yield nattokinase production and therapeutic potential in obesity management.Journal of animal science and biotechnology · 2026Article
- Enhanced production of Nattokinase by Bacillus aryabhattai RP6 isolated from fermented Brassica oleracea.BMC biotechnology · 2026Article
- Statistical optimization of fermentation conditions for enhanced production of Nattokinase from Bacillus subtilis MM26.BMC biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn increase in worldwide death rates attributed to ischemic stroke and myocardial infarction explains the demand to search for new thrombolytic drugs. The current study investigates the therapeutic effect of Nattokinase, a fibrinolytic protein from the mutant strain Bacillus subtilis VITMS 2 isolated from fermented milk of Vigna unguiculata.
resultsThe enzyme production was improved using random mutagenesis combined with statistical optimization through composite central design (CCD) with agro-residual substrates. Among all the different combinations employed, 10% (v/v) cane molasses, 12.5 g/L soybean waste, 12.5 g/L eggshell powder, and 27.5 g/L brewer's spent grain demonstrated a significant influence on fibrinolytic enzyme yield was 4639.43 ± 10.65 FU/mL (Fibrinolytic units/milliliter). This represents a ~ 37.75-fold increase when compared to the unoptimized wild-type strain. The CCD model demonstrated high significance (p < 0.0001) with a strong correlation (R
conclusionThe combination of strain improvement through mutagenesis and media optimization enhanced Nattokinase production, offering a promising approach to develop an enzyme therapy for ischemic stroke and myocardial infarction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.